Invesco Ltd. Sells 506,118 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Invesco Ltd. reduced its position in Applied Therapeutics, Inc. (NASDAQ:APLT) by 90.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 53,499 shares of the company’s stock after selling 506,118 shares during the period. Invesco Ltd.’s holdings in Applied Therapeutics were worth $46,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Private Advisor Group LLC purchased a new stake in shares of Applied Therapeutics during the fourth quarter valued at $35,000. Intech Investment Management LLC lifted its holdings in Applied Therapeutics by 176.1% in the fourth quarter. Intech Investment Management LLC now owns 52,631 shares of the company’s stock valued at $45,000 after acquiring an additional 33,567 shares during the period. Barclays PLC grew its position in Applied Therapeutics by 186.1% during the third quarter. Barclays PLC now owns 200,012 shares of the company’s stock valued at $1,702,000 after buying an additional 130,102 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in Applied Therapeutics by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock worth $268,000 after acquiring an additional 47,983 shares during the period. Finally, Norges Bank bought a new position in Applied Therapeutics in the 4th quarter worth $208,000. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Stock Down 5.5 %

Shares of APLT opened at $0.43 on Tuesday. The business has a 50-day simple moving average of $0.44 and a two-hundred day simple moving average of $2.39. The stock has a market cap of $61.57 million, a price-to-earnings ratio of -0.27 and a beta of 2.00. Applied Therapeutics, Inc. has a 52 week low of $0.30 and a 52 week high of $10.62.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.61 million. On average, equities analysts anticipate that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.